Literature DB >> 34362472

No consensus about consensus?

Ludwig Kappos1.   

Abstract

Entities:  

Year:  2021        PMID： 34362472     DOI： 10.1186/s42466-021-00144-x

Source DB:  PubMed          Journal:  Neurol Res Pract        ISSN： 2524-3489


× No keyword cloud information.
  10 in total

Review 1.  Escalating immunotherapy of multiple sclerosis.Austrian-German- Swiss Multiple Sclerosis Therapy Consensus Group [MSTCG].

Authors:  P Rieckmann; K V Toyka
Journal:  Eur Neurol       Date:  1999       Impact factor: 1.710

2.  Predictive value of clinical characteristics for 'benign' multiple sclerosis.

Authors:  G S M Ramsaransing; J De Keyser
Journal:  Eur J Neurol       Date:  2007-08       Impact factor: 6.089

3.  Early versus later treatment start in multiple sclerosis: a register-based cohort study.

Authors:  T A Chalmer; L M Baggesen; M Nørgaard; N Koch-Henriksen; M Magyari; P S Sorensen
Journal:  Eur J Neurol       Date:  2018-07-09       Impact factor: 6.089

Review 4.  Escalating immunotherapy of multiple sclerosis--new aspects and practical application.

Authors:  P Rieckmann; K V Toyka; C Bassetti; K Beer; S Beer; U Buettner; M Chofflon; M Götschi-Fuchs; K Hess; L Kappos; J Kesselring; N Goebels; H-P Ludin; H Mattle; M Schluep; C Vaney; U Baumhackl; T Berger; F Deisenhammer; F Fazekas; M Freimüller; H Kollegger; W Kristoferitsch; H Lassmann; H Markut; S Strasser-Fuchs; K Vass; H Altenkirch; S Bamborschke; K Baum; R Benecke; W Brück; D Dommasch; W G Elias; A Gass; W Gehlen; J Haas; G Haferkamp; F Hanefeld; H-P Hartung; C Heesen; F Heidenreich; R Heitmann; B Hemmer; T Hense; R Hohlfeld; R W C Janzen; G Japp; S Jung; E Jügelt; J Koehler; W Kölmel; N König; K Lowitzsch; U Manegold; A Melms; J Mertin; P Oschmann; H-F Petereit; M Pette; D Pöhlau; D Pohl; S Poser; M Sailer; S Schmidt; G Schock; M Schulz; S Schwarz; D Seidel; N Sommer; M Stangel; E Stark; A Steinbrecher; H Tumani; R Voltz; F Weber; W Weinrich; R Weissert; H Wiendl; H Wiethölter; U Wildemann; U K Zettl; F Zipp; R Zschenderlein; G Izquierdo; A Kirjazovas; L Packauskas; D Miller; B Koncan Vracko; A Millers; A Orologas; M Panellus; C J M Sindic; M Bratic; A Svraka; N R Vella; Z Stelmasiak; K Selmaj; H Bartosik-Psujik; K Mitosek-Szewczyk; E Belniak; A Mochecka; A Bayas; A Chan; P Flachenecker; R Gold; B Kallmann; V Leussink; M Mäurer; K Ruprecht; G Stoll; F X Weilbach
Journal:  J Neurol       Date:  2004-11       Impact factor: 4.849

5.  Stopping disease-modifying therapy in relapsing and progressive multiple sclerosis.

Authors:  Hans-Peter Hartung; Sven G Meuth; Deborah M Miller; Giancarlo Comi
Journal:  Curr Opin Neurol       Date:  2021-05-14       Impact factor: 5.710

Review 6.  Narrative review of the literature on adherence to disease-modifying therapies among patients with multiple sclerosis.

Authors:  Joseph Menzin; Christina Caon; Christine Nichols; Leigh Ann White; Mark Friedman; Michael W Pill
Journal:  J Manag Care Pharm       Date:  2013 Jan-Feb

7.  Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial.

Authors:  Jerry S Wolinsky; Douglas L Arnold; Bruno Brochet; Hans-Peter Hartung; Xavier Montalban; Robert T Naismith; Marianna Manfrini; James Overell; Harold Koendgen; Annette Sauter; Iain Bennett; Stanislas Hubeaux; Ludwig Kappos; Stephen L Hauser
Journal:  Lancet Neurol       Date:  2020-10-29       Impact factor: 44.182

8.  Medication adherence in multiple sclerosis as a potential model for other chronic diseases: a population-based cohort study.

Authors:  Charity Evans; Ruth Ann Marrie; Shenzhen Yao; Feng Zhu; Randy Walld; Helen Tremlett; David Blackburn; Elaine Kingwell
Journal:  BMJ Open       Date:  2021-02-05       Impact factor: 2.692

9.  Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP).

Authors:  Helmut Butzkueven; Ludwig Kappos; Heinz Wiendl; Maria Trojano; Tim Spelman; Ih Chang; Rachna Kasliwal; Seema Jaitly; Nolan Campbell; Pei-Ran Ho; Stephanie Licata
Journal:  J Neurol Neurosurg Psychiatry       Date:  2020-03-31       Impact factor: 10.154

10.  Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension.

Authors:  Stephen L Hauser; Ludwig Kappos; Douglas L Arnold; Amit Bar-Or; Bruno Brochet; Robert T Naismith; Anthony Traboulsee; Jerry S Wolinsky; Shibeshih Belachew; Harold Koendgen; Victoria Levesque; Marianna Manfrini; Fabian Model; Stanislas Hubeaux; Lahar Mehta; Xavier Montalban
Journal:  Neurology       Date:  2020-07-20       Impact factor: 9.910
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.